SCHEMBL4884084

SCHEMBL4884084

CN(C)[C@H]1CCN(C(=O)Nc2cc(Oc3ccc(NC(=O)N4CCN(c5ccc(F)cc5)C4=O)cc3F)ccn2)C1

nearest known ligand 0.63

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MET P08581 17/20 0.63
KDR P35968 3/20 0.63
BRAF P15056 1/20 0.53
AXL P30530 6/20 0.51
RIPK2 O43353 1/20 0.48
RIPK1 Q13546 1/20 0.48
RIPK3 Q9Y572 1/20 0.48
TYRO3 Q06418 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4884088 1.00 MET (0.63) METKDRBRAFAXLRIPK2
SCHEMBL4887351 1.00 MET (0.63) METKDRBRAFAXLRIPK2
SCHEMBL4884342 0.94 MET (0.70) METKDRBRAF
SCHEMBL4880061 0.94 MET (0.70) METKDRBRAF
SCHEMBL4880056 0.94 MET (0.70) METKDRBRAF
SCHEMBL4887103 0.87 AXL (0.62) METKDRAXLRIPK2RIPK1
SCHEMBL4330515 0.86 KDR (0.58) METKDRBRAFAXL
SCHEMBL4321846 0.86 KDR (0.58) METKDRBRAFAXL
SCHEMBL3560402 0.84 MET (0.58) METKDRBRAFAXLRIPK2
SCHEMBL13038449 0.84 MET (0.58) METKDRBRAFAXLRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160046619-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2016-02-18 US disclosed
US-20160046619-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2016-02-18 US disclosed
US-9133183-B2 Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-09-15 US disclosed
US-9133183-B2 Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-09-15 US disclosed
US-20140315917-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-10-23 US disclosed
US-20140315917-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-10-23 US disclosed
WO-2014145015-A2 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 WO disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046619-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R MET 346/4885KDR 113/4885BRAF 181/4885
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 MET 545/4885KDR 746/4885BRAF 26/4885
US-20140315917-A1 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R MET 346/4885KDR 113/4885BRAF 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.